The Promising Future of GLP-1 Research

The GLP-1 market has significantly grown in recent years, with medications like Ozempic and Mounjaro marketed specifically for type II diabetes treatment and weight management. With this growth, researchers are now considering GLP-1s to treat a wide range of conditions including cardiovascular health, kidney disease, inflammatory diseases, and even neurological disorders. Dr. Rhea brings back fellow colleague and researcher, Dr. Ryan Porter, to share details on his upcoming GLP-1 research which looks at natural methods of boosting GLP-1 production in the body, as opposed to current medications using an agonist approach which means the medication binds to and activates the GLP-1. Dr. Porter holds a bachelor’s degree in exercise science from Brigham Young University - Idaho and a master’s in Health and Human Movement from Utah State University. He completed his doctorate in exercise science at the University of South Carolina and post-doctoral training at the University of South Carolina School of Medicine Greenville. His research interests are in the areas of adaptation of lipoprotein subfractions in response to exercise and lifestyle behavior change (physical activity and healthy eating) and their effects on community health in terms of biological markers, physiological outcomes and behavior change.